Hulusi Atmaca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hulusi Atmaca has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Elif Kilic Kan
Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Turkiye
6 shared publications - Ramis Colak
Ondokuz Mayis University Faculty of Medicine Department of Endocrinology and Metabolism Samsun Turkey Ondokuz Mayis University, Faculty of Medicine, Department of Endocrinology and Metabolism, Samsun, Turkey
6 shared publications Aysegul Atmaca
5 shared publicationsCigdem Tura Bahadir
5 shared publications- Gulcin Cengiz Ecemis
Dr. I Sevki Atasagun Government Hospital, Clinic of Endocrinology, Nevsehir, Turkey
4 shared publications - Ahmet Gürel
Department of Biochemistry, School of Medicine, Zonguldak Karaelmans University, Zonguldak, Turkey
1 shared publication
Latest Publications
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
Metastatic thyroid papillary microcarcinomas
Aim: Thyroid papillary carcinomas smaller than 1 cm are called papillary microcarcinomas (PMC). They rarely metastasize to lymph node (LN) and distant areas. The presence of palpable lymphadenopathy at the time of diagnosis shows high risk of recurrence regardless of primary tumor size. We aimed to investigate histopathologic characteristics and recurrence frequency of thyroid PMCs with LN metastasis (LNM). Materials and methods: Thyroid PMC cases with LNM that were followed by our department between 2009 and 2013 were evaluated retrospectively. Result: There were eight patients (one male, seven females) and the average age was 41 years. The initial compliant was neck lump in four patients, three were already followed-up for thyroid nodule and one for parathyroid adenoma. All were undergone total thyroidectomy and neck dissection. All had received radioactive iodine treatment. None had a history for neck radiotherapy or thyroid carinoma in their family. The tumor diameter was ≥5 mm in 75% of patients. The smallest one was 2 mm and the largest one was 9 mm in the diameter. Seven of eight patients had LNM at the time of diagnosis and the other had LNM during follow-up. 25% of patients had lymphovascular invasion, 37% had capsular invasion, and 50% had multifocality. None had extrathyroidal spread. 75% of patients had recurrence during follow-up. 83% of those patients had LNM at the time of diagnosis. 71% of the patients who had LNM at the time of diagnosis had recurrence (Table 1). Table 1 Patients characteristics. Patient Age/gender Tumor size (mm) LNM at the time of diagnosis Follow-up (years) Lymphovascular/capsular invasion Multifocality/number Extrathyroidal spread Recurrence 1 26/F 9 + 1 +/− +/many − + 2 35/F 2 + 1.5 −/− +/2 − + 3 38/F 7 − 9 −/− − − + 4 53/M 6 + 4 +/+ − − + 5 55/F 8 + 8 −/+ − − − 6 41/F 3 + 0.5 −/− − − − 7 40/F 8 + 1 −/− +/3 − + 8 43/F 9 + 2 −/+ +/4 − + +, yes; −, no. Conclusion: Thyroid PMCs generally have a good prognosis. They rarely show recurrence. However, the presence of LNM at the time of diagnosis is the most important factor for recurrence risk.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
Metastatic thyroid papillary microcarcinomas
Aim: Thyroid papillary carcinomas smaller than 1 cm are called papillary microcarcinomas (PMC). They rarely metastasize to lymph node (LN) and distant areas. The presence of palpable lymphadenopathy at the time of diagnosis shows high risk of recurrence regardless of primary tumor size. We aimed to investigate histopathologic characteristics and recurrence frequency of thyroid PMCs with LN metastasis (LNM). Materials and methods: Thyroid PMC cases with LNM that were followed by our department between 2009 and 2013 were evaluated retrospectively. Result: There were eight patients (one male, seven females) and the average age was 41 years. The initial compliant was neck lump in four patients, three were already followed-up for thyroid nodule and one for parathyroid adenoma. All were undergone total thyroidectomy and neck dissection. All had received radioactive iodine treatment. None had a history for neck radiotherapy or thyroid carinoma in their family. The tumor diameter was ≥5 mm in 75% of patients. The smallest one was 2 mm and the largest one was 9 mm in the diameter. Seven of eight patients had LNM at the time of diagnosis and the other had LNM during follow-up. 25% of patients had lymphovascular invasion, 37% had capsular invasion, and 50% had multifocality. None had extrathyroidal spread. 75% of patients had recurrence during follow-up. 83% of those patients had LNM at the time of diagnosis. 71% of the patients who had LNM at the time of diagnosis had recurrence (Table 1). Table 1 Patients characteristics. Patient Age/gender Tumor size (mm) LNM at the time of diagnosis Follow-up (years) Lymphovascular/capsular invasion Multifocality/number Extrathyroidal spread Recurrence 1 26/F 9 + 1 +/− +/many − + 2 35/F 2 + 1.5 −/− +/2 − + 3 38/F 7 − 9 −/− − − + 4 53/M 6 + 4 +/+ − − + 5 55/F 8 + 8 −/+ − − − 6 41/F 3 + 0.5 −/− − − − 7 40/F 8 + 1 −/− +/3 − + 8 43/F 9 + 2 −/+ +/4 − + +, yes; −, no. Conclusion: Thyroid PMCs generally have a good prognosis. They rarely show recurrence. However, the presence of LNM at the time of diagnosis is the most important factor for recurrence risk.
- 1 April 2013
- Published by Bioscientifica in Endocrine Abstracts
Postmenopausal hirsutism and hyperandrogenemia due to granulosa cell tumor of the ovary
Inroduction: Progressive baldness and severe hirsutism associated with granulosa cell tumor of ovaries are rare conditions in women. Reported cases are usually pubertal girls and young women. Here, we report a case of postmenopausal baldness and hirsutism due to granulosa cell tumor of the ovary. Case report: A 62 year-old woman presented with baldness and hirsutism on her face, body and back for 3 years. She had menarche at 14 years and menopause at 52 years. She had regular menstrual periods until menopause. She had history of infertility which was refractory to treatment and impaired fasting glucose. Four years ago, she had undergone left oopherectomy due to an ovarian cyst which was benign in histological examination. On physical examination, Ferriman–Gallwey index was 24 with severe hirsutism on her face, body and back and male pattern baldness on her scalp. She was normotensive, her body mass index was 34 kg/m2 and there was no cliteromegaly. Hormonal profile revealed elevated total testosterone, 5.31 ng/ml (0.06–0.82) and free testosterone, 18 pg/ml (0.29–3.18), low FSH 2.35 mIU/ml (25.8–134.8) and LH 3.45 mIU/ml (7.7–59) for postmenopausal women. Estradiol, prolactin, dehydroepiandrosterone sulphate, 17-hydroxyprogesterone, TSH and IGF1 levels were normal. She had 46, XX karyotype. Magnetic resonance imaging of abdomen and pelvis revealed a right ovarian mass. She underwent laparoscopically-assisted hysterectomy and right salpingo-oophorectomy. Microscopic examination of the right ovarian tumor revealed granulosa cell tumor. Three months after surgery, total and free testosterone levels decreased to 0.121 ng/ml and 0.68 pg/ml, respectively. FSH and LH rised to 25.76 and 21.31 mIU/ml, respectively. At 9 months, her testosterone levels were still low and hirsutism and baldness improved. Conclusions: Although granulosa cell tumors are generally associated with manifestations of hyperestrogenism, our patient was in hyperandrogenemic and improved both clinically and biochemically after the operation.
- 1 April 2013
- Published by Bioscientifica in Endocrine Abstracts
Postmenopausal hirsutism and hyperandrogenemia due to granulosa cell tumor of the ovary
Inroduction: Progressive baldness and severe hirsutism associated with granulosa cell tumor of ovaries are rare conditions in women. Reported cases are usually pubertal girls and young women. Here, we report a case of postmenopausal baldness and hirsutism due to granulosa cell tumor of the ovary. Case report: A 62 year-old woman presented with baldness and hirsutism on her face, body and back for 3 years. She had menarche at 14 years and menopause at 52 years. She had regular menstrual periods until menopause. She had history of infertility which was refractory to treatment and impaired fasting glucose. Four years ago, she had undergone left oopherectomy due to an ovarian cyst which was benign in histological examination. On physical examination, Ferriman–Gallwey index was 24 with severe hirsutism on her face, body and back and male pattern baldness on her scalp. She was normotensive, her body mass index was 34 kg/m2 and there was no cliteromegaly. Hormonal profile revealed elevated total testosterone, 5.31 ng/ml (0.06–0.82) and free testosterone, 18 pg/ml (0.29–3.18), low FSH 2.35 mIU/ml (25.8–134.8) and LH 3.45 mIU/ml (7.7–59) for postmenopausal women. Estradiol, prolactin, dehydroepiandrosterone sulphate, 17-hydroxyprogesterone, TSH and IGF1 levels were normal. She had 46, XX karyotype. Magnetic resonance imaging of abdomen and pelvis revealed a right ovarian mass. She underwent laparoscopically-assisted hysterectomy and right salpingo-oophorectomy. Microscopic examination of the right ovarian tumor revealed granulosa cell tumor. Three months after surgery, total and free testosterone levels decreased to 0.121 ng/ml and 0.68 pg/ml, respectively. FSH and LH rised to 25.76 and 21.31 mIU/ml, respectively. At 9 months, her testosterone levels were still low and hirsutism and baldness improved. Conclusions: Although granulosa cell tumors are generally associated with manifestations of hyperestrogenism, our patient was in hyperandrogenemic and improved both clinically and biochemically after the operation.
- 1 April 2013
- Published by Bioscientifica in Endocrine Abstracts
Cases with adrenocortical carcinoma
Introduction: Adrenocortical carcinoma (ACC) is a rare cancer (estimated incidence, 0.7 to 2.0 cases per 1 million population per year) with a poor prognosis. Even after seemingly complete surgical resection, most patients develop recurrence within 5 years. The 5-year survival rate is <15% among patients with metastatic disease. Methods: We present the results of six patients with adrenocortical carcinoma followed in our clinic. Results: The mean age was 54 years and female/male ratio was 2/4. Tumor size ranges from 6 to 14 cm. At baseline, only one patient had high dehydroxyepiandrosterone-sulphate levels (Patient 1). Tumor was non-functional in 5 patients. One patient presented with Cushing’s syndrome and hypercortisolism was documented in her laboratory evaluations (Patient 4). All of them were treated with surgery. In one patient, tumor was bilateral and in others were on left adrenal. The patient with bilateral tumors had lung metastasis at diagnosis (Patient 3). Another patient developed lung metastasis 2 years after the operation (Patient 1). Patient 4 had lung metastasis and Patient 6 had lung, liver and lymph node metastasis. One patient was lost-to follow-up after the operation (Patient 5). Three patients died 5 months after the operation. Three out of six patients received mitotane after the operation. Two patients could not receive mitotane because of elevated liver enzymes (Patients 4 and 6). Patient 1 developed lung metastasis 2 years after the diagnosis and is now receiving chemotherapy (cisplatin-etoposide) with mitotane. This patient is being followed in our clinic for 53 months. Conclusion: Treatment options for advanced ACC are limited. Even after successful complete excision of the tumor, local or distant metastatic recurrences are frequent. However, some patients on regular follow-up and mitotane as adjuvant therapy may benefit from treatment as seen in Patient 1.
- 1 April 2013
- Published by Bioscientifica in Endocrine Abstracts
Cases with adrenocortical carcinoma
Introduction: Adrenocortical carcinoma (ACC) is a rare cancer (estimated incidence, 0.7 to 2.0 cases per 1 million population per year) with a poor prognosis. Even after seemingly complete surgical resection, most patients develop recurrence within 5 years. The 5-year survival rate is <15% among patients with metastatic disease. Methods: We present the results of six patients with adrenocortical carcinoma followed in our clinic. Results: The mean age was 54 years and female/male ratio was 2/4. Tumor size ranges from 6 to 14 cm. At baseline, only one patient had high dehydroxyepiandrosterone-sulphate levels (Patient 1). Tumor was non-functional in 5 patients. One patient presented with Cushing’s syndrome and hypercortisolism was documented in her laboratory evaluations (Patient 4). All of them were treated with surgery. In one patient, tumor was bilateral and in others were on left adrenal. The patient with bilateral tumors had lung metastasis at diagnosis (Patient 3). Another patient developed lung metastasis 2 years after the operation (Patient 1). Patient 4 had lung metastasis and Patient 6 had lung, liver and lymph node metastasis. One patient was lost-to follow-up after the operation (Patient 5). Three patients died 5 months after the operation. Three out of six patients received mitotane after the operation. Two patients could not receive mitotane because of elevated liver enzymes (Patients 4 and 6). Patient 1 developed lung metastasis 2 years after the diagnosis and is now receiving chemotherapy (cisplatin-etoposide) with mitotane. This patient is being followed in our clinic for 53 months. Conclusion: Treatment options for advanced ACC are limited. Even after successful complete excision of the tumor, local or distant metastatic recurrences are frequent. However, some patients on regular follow-up and mitotane as adjuvant therapy may benefit from treatment as seen in Patient 1.
- 1 April 2013
- Published by Bioscientifica in Endocrine Abstracts
A patient osteogenesis imperfecta with osteoporosis
Introduction: Osteogenesis imperfecta (OI) is a congenital, generalized connective tissue disorder characterized by severe osteoporosis and bone fragility. OI is most commonly caused by mutations in genes encoding the α-1 and α-2 chains of type I collagen or proteins involved in posttranslational modification of type I collagen. Although, no controlled studies are done, bisphosphonates are used for the treatment of OI. I.v. bisphosphonates are reported to be more effective for pain conrol than oral bisphosphonates. Here, we report the results of a patient with OI and osteoporosis who received cyclic i.v. pamidronate. Case report: A 31 years old man with OI and osteoporosis admitted with generalized bone pain. He had been using alendronate 70 mg/week p.o. for 2 years with no improvement in bone mineral density (BMD) and pain. I.v. cyclic pamidronate was started at a dose of 60 mg/day for 3 days every 4 months. BMD was assessed at baseline, at 6 and 12 months of treatment. Short form-36 (SF-36) questionnaire was used to evaluate his quality of life at baseline and at 12 months. His vertabral BMD T-score was −4.2 and femur neck T-score was −2.0 at baseline. At 6th month, his vertabral BMD T-score was −3.6 and femur neck T-score was −1.6. At 12th month, his vertabral BMD T-score was −3.6 and femur neck T-score was −1.4. A significant improvement was observed in his SF-36 scores at 12th month. No adverse effects were observed due to treatment. Conclusions: OI is a rare disease and no treatment protocol has been shown to be superior to others. I.v. bisphosphonates may be better for pain control than oral bisphosphonates. This case shows the improvement of BMD and quality of life after 1 year treatment with i.v. pamidronate, which not achived with oral alendronate.
- 1 April 2013
- Published by Bioscientifica in Endocrine Abstracts
A patient osteogenesis imperfecta with osteoporosis
Introduction: Osteogenesis imperfecta (OI) is a congenital, generalized connective tissue disorder characterized by severe osteoporosis and bone fragility. OI is most commonly caused by mutations in genes encoding the α-1 and α-2 chains of type I collagen or proteins involved in posttranslational modification of type I collagen. Although, no controlled studies are done, bisphosphonates are used for the treatment of OI. I.v. bisphosphonates are reported to be more effective for pain conrol than oral bisphosphonates. Here, we report the results of a patient with OI and osteoporosis who received cyclic i.v. pamidronate. Case report: A 31 years old man with OI and osteoporosis admitted with generalized bone pain. He had been using alendronate 70 mg/week p.o. for 2 years with no improvement in bone mineral density (BMD) and pain. I.v. cyclic pamidronate was started at a dose of 60 mg/day for 3 days every 4 months. BMD was assessed at baseline, at 6 and 12 months of treatment. Short form-36 (SF-36) questionnaire was used to evaluate his quality of life at baseline and at 12 months. His vertabral BMD T-score was −4.2 and femur neck T-score was −2.0 at baseline. At 6th month, his vertabral BMD T-score was −3.6 and femur neck T-score was −1.6. At 12th month, his vertabral BMD T-score was −3.6 and femur neck T-score was −1.4. A significant improvement was observed in his SF-36 scores at 12th month. No adverse effects were observed due to treatment. Conclusions: OI is a rare disease and no treatment protocol has been shown to be superior to others. I.v. bisphosphonates may be better for pain control than oral bisphosphonates. This case shows the improvement of BMD and quality of life after 1 year treatment with i.v. pamidronate, which not achived with oral alendronate.
- 1 April 2013
- Published by Bioscientifica in Endocrine Abstracts
An acromegalic patient with giant tumor
Introduction: Acromegaly is a disease caused by excessive secretion of GH. The cause of acromegaly is GH secreting pituitary adenoam in 99% of the cases. It is estimated that 5% of pituitary adenomas become invasive and may grow to gigantic sizes (>4 cm in diameter). Here, we present a 31 years old acromegalic woman with a delayed diagnosis of a giant invasive pituiatary adenoma. Case report: A 31-year-old woman admitted to our hospital for oligomenorhea and loss of vision. She had a history of infertility for 10 years. She received IVF five times. Her FSH was 0.43 (3.5–12.5) mU/ml, LH was 0.07 (2.4–12.6) mU/ml, prolactin was 27 ng/ml (4.7–23) and IGF1 was 984 ng/ml (116–307 for her age). Her nadir GH level during a 75 g oral glucose tolerence test was 14.8 mg/dl. Pituitary magnetic resonance imaging revealed a 72×47×68 mm macroadenoma with necrotic componenets which invades suprasellar region and sphenoid sinus and destructs sphenoid bone. Despite a giant macroadenoma her thyrotrophes and corticotrophes were not affected. She had normal thyroid and adrenal fucntions. She had transcranial removal of the adenoma and histopathological diagnosis was eosinophilic somatotroph adenoma. Immunhistochemical staining was positive for GH. Postoperatively, she had severe hypernatremia and she was followed in intensive care unit. She died in her second postoperative day with severe electrolyte imbalance. Conclusions: Delayed diagnosis of acromegaly may lead to growth of a giant macroadenoma which then increases the likelihood of morbidity, postoperative complications and mortality.
- 1 April 2013
- Published by Bioscientifica in Endocrine Abstracts
An acromegalic patient with giant tumor
Introduction: Acromegaly is a disease caused by excessive secretion of GH. The cause of acromegaly is GH secreting pituitary adenoam in 99% of the cases. It is estimated that 5% of pituitary adenomas become invasive and may grow to gigantic sizes (>4 cm in diameter). Here, we present a 31 years old acromegalic woman with a delayed diagnosis of a giant invasive pituiatary adenoma. Case report: A 31-year-old woman admitted to our hospital for oligomenorhea and loss of vision. She had a history of infertility for 10 years. She received IVF five times. Her FSH was 0.43 (3.5–12.5) mU/ml, LH was 0.07 (2.4–12.6) mU/ml, prolactin was 27 ng/ml (4.7–23) and IGF1 was 984 ng/ml (116–307 for her age). Her nadir GH level during a 75 g oral glucose tolerence test was 14.8 mg/dl. Pituitary magnetic resonance imaging revealed a 72×47×68 mm macroadenoma with necrotic componenets which invades suprasellar region and sphenoid sinus and destructs sphenoid bone. Despite a giant macroadenoma her thyrotrophes and corticotrophes were not affected. She had normal thyroid and adrenal fucntions. She had transcranial removal of the adenoma and histopathological diagnosis was eosinophilic somatotroph adenoma. Immunhistochemical staining was positive for GH. Postoperatively, she had severe hypernatremia and she was followed in intensive care unit. She died in her second postoperative day with severe electrolyte imbalance. Conclusions: Delayed diagnosis of acromegaly may lead to growth of a giant macroadenoma which then increases the likelihood of morbidity, postoperative complications and mortality.
- 9 February 2013
- Published by Springer Nature in International Ophthalmology
- Vol. 33 (5) , 521-525
Visual field defects in 23 acromegalic patients
- 9 February 2013
- Published by Springer Nature in International Ophthalmology
- Vol. 33 (5) , 521-525
Visual field defects in 23 acromegalic patients
- 1 January 2013
- Published by Marmara University in Marmara Medical Journal
The Results Of Pegvisomant Treatment In Acromegaly And Review of The Literature
- 1 January 2013
- Published by Marmara University in Marmara Medical Journal
The Results Of Pegvisomant Treatment In Acromegaly And Review of The Literature
- 3 July 2012
- Published by Springer Nature in Pituitary
- Vol. 16 (2) , 202-207
Lymphocyte subpopulations in Sheehan’s syndrome
The role of autoimmunity in the development of Sheehan’s syndrome is obscure. There are a limited number of studies investigating the immunological alterations accompanying Sheehan’s Syndrome. Our objective was to evaluate lymphocyte subsets in these patients. We conducted a cross-sectional clinical study. Cytofluorometry was used for the immunophenotyping of peripheral blood leukocytes from patients with Sheehan’s syndrome followed up in the endocrine clinic during 2005–2009. Fifteen consecutive patients (mean age 61.6 ± 11.3, range 34–75 years) and 25 healthy controls (mean age 56.7 ± 10.6, range 34–80 years) were included. There was no statistically significant difference between the groups in terms of mean age. The percentages of CD19+, CD16+/56+, CD8+28−, γδTCR+, CD8+; the total lymphocyte counts; and the ratio of CD8+28−/CD8+28+ were similar (p > 0.05) between patients and controls. Whereas the leucocyte counts (p = 0.003), the percentage of CD3+DR+ (p < 0.001), CD8+28+ (p = 0.030), CD4+CD25+ (p = 0.007), the ratio of CD3+DR+/CD3 (p < 0.001) were higher; the percentage of CD3 (p = 0.020), CD4 (p < 0.001) and the ratio of CD4/CD8 (p = 0.006) were lower in patients with Sheehan’s syndrome compared to healthy controls. There was a positive correlation between the duration of illness and the percentage of CD3+DR+ (r = 0.53, p = 0.03) expression. Some peripheral lymphocyte cell subsets show marked variation in patients with Sheehan’s syndrome in comparison to matched healthy subjects, which may have implications for altered immune regulation in these patients. High CD3+DR+ expression that correlates with the duration of illness in Sheehan’s patients is suggestive of an ongoing inflammation accompanying the slow progression of pituitary dysfunction in Sheehan’s syndrome. It is not clear if these cellular alterations contribute to the cause or consequence of pituitary deficiency in Sheehan’s syndrome.
- 3 July 2012
- Published by Springer Nature in Pituitary
- Vol. 16 (2) , 202-207
Lymphocyte subpopulations in Sheehan’s syndrome
The role of autoimmunity in the development of Sheehan’s syndrome is obscure. There are a limited number of studies investigating the immunological alterations accompanying Sheehan’s Syndrome. Our objective was to evaluate lymphocyte subsets in these patients. We conducted a cross-sectional clinical study. Cytofluorometry was used for the immunophenotyping of peripheral blood leukocytes from patients with Sheehan’s syndrome followed up in the endocrine clinic during 2005–2009. Fifteen consecutive patients (mean age 61.6 ± 11.3, range 34–75 years) and 25 healthy controls (mean age 56.7 ± 10.6, range 34–80 years) were included. There was no statistically significant difference between the groups in terms of mean age. The percentages of CD19+, CD16+/56+, CD8+28−, γδTCR+, CD8+; the total lymphocyte counts; and the ratio of CD8+28−/CD8+28+ were similar (p > 0.05) between patients and controls. Whereas the leucocyte counts (p = 0.003), the percentage of CD3+DR+ (p < 0.001), CD8+28+ (p = 0.030), CD4+CD25+ (p = 0.007), the ratio of CD3+DR+/CD3 (p < 0.001) were higher; the percentage of CD3 (p = 0.020), CD4 (p < 0.001) and the ratio of CD4/CD8 (p = 0.006) were lower in patients with Sheehan’s syndrome compared to healthy controls. There was a positive correlation between the duration of illness and the percentage of CD3+DR+ (r = 0.53, p = 0.03) expression. Some peripheral lymphocyte cell subsets show marked variation in patients with Sheehan’s syndrome in comparison to matched healthy subjects, which may have implications for altered immune regulation in these patients. High CD3+DR+ expression that correlates with the duration of illness in Sheehan’s patients is suggestive of an ongoing inflammation accompanying the slow progression of pituitary dysfunction in Sheehan’s syndrome. It is not clear if these cellular alterations contribute to the cause or consequence of pituitary deficiency in Sheehan’s syndrome.
- 1 February 2008
- Vol. 14 (2) , CR97-101
The evaluation of serum cystatin C, malondialdehyde, and total antioxidant status in patients with metabolic syndrome.
This study was designed to determine if serum cystatin C (Cys C) levels are affected by metabolic syndome and whether they correlate with lipid peroxidation and total antioxidant status (TAS) in this disorder. Cases with metabolic syndrome diagnosed according to the ATP III criteria (18 females, 12 males) were compared with healthy control subjects (20 females, 17 males) matched by age and gender. Plasma Cys C, malondialdehyde (MDA), and TAS levels were studied. Compared with the controls, Cys C and MDA levels were significantly higher (p<0.001 and p<0.001, respectively), whereas TAS was lower (p<0.001) in metabolic syndrome patients. A significant positive correlation between MDA and Cys C (r=0.308, p<0.05) and a significant negative correlation between TAS and Cys C levels (r=-0.358, p<0.01) were found. As Cys C and MDA levels increased but TAS decreased, Cys C may be an important indicator in the pathogenesis of metabolic syndrome.
- 1 February 2008
- Vol. 14 (2) , CR97-101
The evaluation of serum cystatin C, malondialdehyde, and total antioxidant status in patients with metabolic syndrome.
This study was designed to determine if serum cystatin C (Cys C) levels are affected by metabolic syndome and whether they correlate with lipid peroxidation and total antioxidant status (TAS) in this disorder. Cases with metabolic syndrome diagnosed according to the ATP III criteria (18 females, 12 males) were compared with healthy control subjects (20 females, 17 males) matched by age and gender. Plasma Cys C, malondialdehyde (MDA), and TAS levels were studied. Compared with the controls, Cys C and MDA levels were significantly higher (p<0.001 and p<0.001, respectively), whereas TAS was lower (p<0.001) in metabolic syndrome patients. A significant positive correlation between MDA and Cys C (r=0.308, p<0.05) and a significant negative correlation between TAS and Cys C levels (r=-0.358, p<0.01) were found. As Cys C and MDA levels increased but TAS decreased, Cys C may be an important indicator in the pathogenesis of metabolic syndrome.
- Open Access
- 16 December 2002
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 1 (1) , 6
Antituberculosis drug resistance patterns in two regions of Turkey: a retrospective analysis
The emergence of Mycobacterium tuberculosis strains resistant to antituberculosis agents has recently received increased attention owing largely to the dramatic outbreaks of multi drug resistance tuberculosis (MDR-TB). Patients residing in Zonguldak and Kayseri provinces of Turkey with, pulmonary tuberculosis diagnosed between 1972 and 1999 were retrospectively identified. Drug susceptibility tests had been performed for isoniazid (INH), rifampin (RIF), streptomycin (SM), ethambutol (EMB) and thiacetasone (TH) after isolation by using the resistance proportion method. Total 3718 patients were retrospectively studied. In 1972-1981, resistance rates for to SM and INH were found to be 14.8% and 9.8% respectively (n: 2172). In 1982-1991 period, resistance rates for INH, SM, RIF, EMB and TH were 14.2%, 14.4%, 10.5%, 2.7% and 2.9% (n: 683), while in 1992-1999 period 14.4%, 21.1%, 10.6%, 2.4% and 3.7% respectively (n: 863). Resistance rates were highest for SM and INH in three periods. MDR-TB patients constituted 7.3% and 6.6% of 1982-1991 and 1992-1999 periods (p > 0.05). This study demonstrates the importance of resistance rates for TB. Continued surveillance and immediate therapeutic decisions should be undertaken in order to prevent the dissemination of such resistant strains.
- 16 December 2002
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 1 (1) , 6
Open AccessAntituberculosis drug resistance patterns in two regions of Turkey: a retrospective analysis
The emergence of Mycobacterium tuberculosis strains resistant to antituberculosis agents has recently received increased attention owing largely to the dramatic outbreaks of multi drug resistance tuberculosis (MDR-TB). Patients residing in Zonguldak and Kayseri provinces of Turkey with, pulmonary tuberculosis diagnosed between 1972 and 1999 were retrospectively identified. Drug susceptibility tests had been performed for isoniazid (INH), rifampin (RIF), streptomycin (SM), ethambutol (EMB) and thiacetasone (TH) after isolation by using the resistance proportion method. Total 3718 patients were retrospectively studied. In 1972-1981, resistance rates for to SM and INH were found to be 14.8% and 9.8% respectively (n: 2172). In 1982-1991 period, resistance rates for INH, SM, RIF, EMB and TH were 14.2%, 14.4%, 10.5%, 2.7% and 2.9% (n: 683), while in 1992-1999 period 14.4%, 21.1%, 10.6%, 2.4% and 3.7% respectively (n: 863). Resistance rates were highest for SM and INH in three periods. MDR-TB patients constituted 7.3% and 6.6% of 1982-1991 and 1992-1999 periods (p > 0.05). This study demonstrates the importance of resistance rates for TB. Continued surveillance and immediate therapeutic decisions should be undertaken in order to prevent the dissemination of such resistant strains.